Monitoring of drug resistance in therapy-naïve HIV infected patients and detection of African HIV subtypes in Hungary

Acta Microbiologica et Immunologica Hungarica

Volumn 57, Issue 1, 2010, Pages 55-68

  Kanizsai, Szilvia ^a   Ghidan A ^a   Újhelyi, Eszter ^b   Banhegyi D ^b   Nagy, K ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Szent László St Ladislas Hospital   (Hungary)

Author keywords

CRF; Genotyping; HIV 1 drug resistant mutants; HIV 1 subtypes; Therapy na ve HIV infected patients

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; ANTIVIRAL RESISTANCE; ARTICLE; ASIA; CLINICAL ARTICLE; CODON; EUROPE; FEMALE; GENE MUTATION; GENOTYPE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNGARY; MOUSE; NONHUMAN; STRUCTURAL GENE; VIRUS RECOMBINANT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950278297     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.57.2010.1.5     Document Type: Article

References (27)

1. Mansky, L. M., Temin, H. M.: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse-transcriptase. J. Virol. 69, 5087-5094 (1995).
2. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., Ho, D. D.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
3. Kils-Hutten, L., Cheynier, R., Wain-Hobson, S., Meyerhans, A.: Phylogenetic reconstruction of intrapatient evolution of human immunodeficiency virus type 1: Predominance of drift and purifying selection. J. Gen. Virol. 82, 1621-1627 (2001).
4. Levy, D. N., Aldrovandi, G. M., Kutsch, O., Shaw, G. M.: Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA 101, 4204-4209 (2004).
5. Suryavanshi, G. W., Dixit, N.: Emergence of recombinant forms of HIV: Dynamics and scaling. PLoS Comput. Biol. 3, e205 (2007).
6. Chen, J., Dang, Q., Unutmaz, D., Pathak, V. K., Maldarelli, F., Powell, D., Hu, W.-S.: Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: Preference in virus entry is important but is not the sole factor. J. Virol. 79, 4140-4149 (2005).
7. Rhodes, T., Wargo, H., Hu, W.-S.: High rates of human immunodeficiency virus type 1 recombination: Near-random segregation of markers one kilobase apart in one round of viral replication. J. Virol. 77, 11193-11200 (2003).
8. Charpentier, C., Nora, T., Tenaillon, O., Clavel, F., Hance, A. J.: Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J. Virol. 80, 2472-2482 (2006).
9. Althaus, C. L., Bonhoeffer, S.: Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J. Virol. 79, 13572-13578 (2005).
10. Clavel, F., Hance, A. J.: Medical progress: HIV drug resistance. N. Engl. J. Med. 350, 1023-1035 (2004).
11. Simon, V., Ho, D. D., Karim, Q. A.: HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368, 489-504 (2006).
12. Nagy, K., Young, M., Baboonian, C., Merson, J., Whittle, P., Oroszlan, S.: Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: Evidence for a role of protease in the early phase. J. Virol. 68, 757-765 (1994).
13. Stephenson, J.: Researchers buoyed by novel HIV drugs: Will expand drug arsenal against resistant virus. JAMA 297 (14), 1535-1536 (2007).
14. Schinazi, R. F., Larder, B. A., Mellors, J.: Mutations in retroviral genes associated to drug resistance: Update 2000-2001. Int. Antivir. News 8, 65-91 (2000).
15. Shafer, R. W.: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15, 247-277 (2002).
16. Lech, W. J., Wang, G., Yang, Y. L., Chee, Y., Dorman, K., McCrae, D., Lazzeroni, L. C., Erickson, J. W., Sinsheimer, J. S., Kaplan, A. H.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70, 2038-2043 (1996).
17. Ribeiro, R. M., Bonhoeffer, S.: Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97, 7681-7686 (2000).
18. Markham, R. B., Wang, W. C., Weisstein, A. E., Wang, Z., Munoz, A., Templeton, A., Margolick, J., Vlahov, D., Quinn, T.: Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc. Natl. Acad. Sci. USA 95, 12568-12573 (1998).
19. Nagy, K., Horváth, A.: 25 years of HIV virus, Orv. Hetil. (Hungarian) 151(4), 133-137 (2010).
20. Nagy, K., Albert J., Bánhegyi, D.: Isolation of human immunodeficiency virus from Hungarian patients with AIDS and ARC. Lab. Diagn. (Hungarian) 15(4), 213-216 (1988).
21. Holguin, A., Lopez, M., Soriano, V.: Reliability of rapid subtyping tool compared to that of phylogenetic analysis for characterization human immunodeficiency virus type 1 non-B subtypes and recombinant forms. J. Clin. Microbiol. 46, 3896-3899 (2008). Acta Microbiologica et Immunologica Hungarica
22. Juhasz, E., Ghidan, A., Kemeny, B., Nagy, K.: Emergence of antiretroviral drug resistance in therapy-naïve HIV infected patients in Hungary. Acta Microbiol. Immunol. Hung. 55(4), 383-394 (2008).
23. Ibe, S., Hattori, J., Fujisaki, S., Shigemi, U., Fujisaki, S., Shimizu, K., Nakamura, K., Kazumi, T., Yokomaku, Y., Mamiya, M., Hamaguchi, M., Kaneda, T.: Trend of drug-resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: An 8-year surveillance from 1999 to 2006. AIDS Research and Human Retroviruses 24(1), 7-14 (2008).
24. Wensing, A. M.: Systemic surveillance of transmission of HIV resistance in Europe. The SPREAD project. Inst. Conf. AIDS, Barcelona, TuPe5370 (2002).
25. Clark, S. A., Shulman, N. S., Bosch, R. J., Mellors, J. W.: Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 20, 981-984 (2006).
26. Nagy, K., Barabás, É., Várkonyi, V., Horváth, A.: Determination of HIV-1 subtype in Hungary by synthetic peptides representing the V3 loop of env. Pathol. Oncol. Res. 2, 268-271 (1996).
27. McCurchan, F.: Understanding the genetic diversity of HIV-1. AIDS 14(Suppl3), S31-S44 (2000).